105 results about "Renal carcinoma" patented technology

The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

The invention belongs to the technical field of biology and new medicines and discloses a chimeric antigen receptor (CAR) iRGD-scFv (G250)-CD8-CD28-CD137-CD3zeta and application thereof. The chimeric antigen receptor is formed by series connection of tumor penetrating peptide iRGD, a single-chain antibody of a humanized anti-human renal carcinoma antigen G250, a hinge region and a transmembrane region of CD8, and intracellular signal structural domains of CD28, CD137 and CD3zeta. The chimeric antigen receptor can be used for modifying T lymphocytes, and the modified T lymphocytes can be used for renal carcinoma treatment.

The invention disclose a pulchritude of neoplasm sera, which made up of peptide metarginase; among of which tumor is that one of breast carcinoma, liver cancer, renal carcinoma, oophoroma, carcinoma of prostate and bladder carcinoma. The invention also disclose the application of pulchritude of neoplasm sera in the clinical diagnosis reagent of preparing detect tumor. Using the tumor clinical diagnosis reagent or kit which is provided by this invention and prepared pulchritude of neoplasm sera, it can detect a guideline and realize preparatory ensure if the tester suffer from malignancy, accomplish the work of health screening with low cost in the short detect time, and provide the reliable basis for the clinical diagnosis.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

The invention relates to a medicament-tumor number 1 capable of killing cancer cells and curing various tumors and cancers and leukemia. The medicament comprises glossy ganoderma, ginseng, herba epimedii, astragalus membranaceus, giant knotweed rhizome, Chinese caterpillar fungus, heartleaf houttuynia herb and liquorice root. The medicament capable of killing cancer cells and curing various tumors and cancers and leukemia is prepared by pure traditional Chinese medicine, is good in treatment effects, less in side effects, short in treatment course and the like, is rapid in effect and high in cure rate, has effects of killing cancer cells and improving human body immunity, has functions of prolonging life and anti-aging and is capable of curing leukemia and various tumors and cancers, such as leukemia, bone cancer, lymphoma, intestinal cancer, liver cancer, renal carcinoma, gastric cancer, pelvic cancer, uterine cancer, cervical cancer, bladder cancer, prostatic cancer, pancreatic cancer, lung cancer, brain cancer, neuroendocrine tumor, mammary cancer and esophageal cancer.

The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.

The invention relates to an ASPL-TFE3 fused renal carcinoma gene probe as well as an application of a kit thereof. Cloned fragments selected by the gene probe are respectively a combination of RP11-634L10, RP11-51H16 and RP11-475F12 and a combination of CTD-2311N12, RP11-416B14, CTD-2522M13, CTD-2516D6, CTD-2312C1, CTD-2248C21 and RP11-959H17. By using the ASPL-TFE3 fused renal carcinoma gene probe, the defects of complexity, time consumption and clinic application unsuitability of RT-PCR and cell karyotyping methods applied in the past are overcome. According to the ASPL-TFE3 fused renal carcinoma gene probe, a unique ASPL-TFE3 fused gene in ASPL-TFE3 fused renal carcinoma is detected by using an FISH technology, so that the renal carcinoma is diagnosed; the gene probe is high in accuracy rate, specificity and success rate, strong in fluorescence signal, simple and rapid in operation and rapid in diagnosis when applied and can be applied to paraffin section; and due to the application of the ASPL-TFE3 fused renal carcinoma gene probe, the specimen detecting range is widened, a novel method for accurately, reliably, simply and conveniently diagnosing the ASPL-TFE3 fused renal carcinoma is established, and the precedent that the ASPL-TFE3 fused renal carcinoma is detected by virtue of FISH is created.

The invention discloses a group of genes for molecular subtyping of renal cell carcinoma and an application of the genes. The group of genes include 44 genes as follows: RHCG gene, RNF128 gene, TMEM255A gene, PCP4 gene, DHRS2 gene, CLDN8 gene, AQP6 gene, SLC18A2 gene, KRT7 gene, SERPINA5 gene, SFTPB gene, DEFB1 gene, MAL gene, ANGPTL4 gene, LCN2 gene, PLIN2 gene, ZNF395 gene, TACSTD2 gene, NDUFA4L2 gene, NNMT gene, HILPDA gene, UMOD gene, SLC12A1 gene, CALB1 gene, C7 gene, S100A2 gene, ASS1 gene, MT1G gene, ABCA8 gene, FOSB gene, MAOB gene, STAP1 gene, TFPI2 gene, AKR1C2 gene, IGFBP6 gene, VCAN gene, FLRT3 gene, MMP7 gene, GSTA1 gene, CRYAB gene, PAH gene, IGFBP1 gene, ATP6V0A4 gene and ALDOB gene. Based upon verification, it is proved that the genes can be used for accurately distinguishing oncocytic adenom, clear cell carcinoma, papillary cell carcinoma chromophobe renal carcinoma; the genes are broad in application scope, high in accuracy rate and short in experimental cycle; and the genes can achieve an important clinical significance for the precise treatment of a patient.

Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumors, and various dosing regimes are given. Tumor reduction has been observed in several tumor types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis, complementing the anti-tumor activity.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and / or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.

The invention relates to an ultra-micronized megestrol acetate in which 100% of particle sizes are smaller than or equal to 10 mu m. The invention also relates to a pharmaceutical composition containing the ultra-micronized megestrol acetate, which comprises an effective quantity of ultra-micronized megestrol acetate and medically acceptable excipient, wherein the effective quantity is 80-160 mg of ultra-micronized megestrol acetate. The pharmaceutical composition can be prepared into dispersing tablets, common tablets and capsules and used for treating advanced breast cancer, advanced endometrial carcinoma, renal carcinoma, prostatic cancer and oophoroma, and can improve the appetite and the cachexia of patients with advanced tumors.

The invention discloses a selectivity inhibitor of a clinical mutant of EGFR protein tyrosine kinase. The selectivity inhibitor of the clinical mutant of EGFR protein tyrosine kinase has a structure which is shown in the formula (1) (The formula (1) is defined in the description), and is a double aromatic nucleus template compound containing quinazoline, pyridopyrimidine or pyrimidopyrimidine. The invention further discloses a preparing method of the compound and an application of the compound as the selectivity inhibitor of the clinical mutant of EGFR protein tyrosine kinase, especially an inhibiting effect of the compound in a T790M-variation EGFR and an application in treating diseases such as renal carcinoma, lung cancer, prostate gland cancer, pancreatic cancer, breast cancer and spongiocytoma, wherein the diseases are related to overexpression of the epidermal growth factor receptor EGFR.

The invention discloses a usage of Jew ear fungal aqueous extract in the preparation of a drug for curing tumors, wherein, the tumors include cervical cancer, ovarian cancer, carcinoma of endometrium, vulva cancer, prostate cancer, parotid gland, thyroid cancer, salivary gland cancer, skin cancer, nasopharyngeal carcinoma, tongue cancer, oral cavity cancer, carcinoma of larynx, encephaloma, carcinoma of gallbladder, renal carcinoma, gingival carcinoma, testicular cancer, penile cancer, multiple myeloma and / or malignant melanoma.

The invention discloses a diagnosis marker and treatment target of renal clear cell carcinoma and belongs to the technical field of gene new application. The diagnosis marker and treatment target is MRO. The diagnosis marker and treatment target has the advantages that the fact that the expression of the marker MRO in a renal clear cell carcinoma is reduced is discovered for the first time, the proliferation, migration and invasion of cancer cells can be lowered by increasing the expression of the MRO, and the MRO serving as the target can be used for treating the renal clear cell carcinoma and renal carcinoma metastasis.

The invention relates to a method for extracting a clam extract freeze-dried powder. The method is characterized by comprising the following steps: cleaning: fresh marine organism clams are cleaned to remove sludge, shells are removed, soft bodies are taken out and cleaned until no bloodiness is left and then drained, thus obtaining a clean material; mashing: particle size is between 0.2cm and 0.4cm; extracting: the clean material mashed is mixed with water by a ratio of 1:1 to 1:2 in an extraction plant for extraction for 2 hours to 6 hours at temperature between 0 DEG C and 10 DEG C, separation, centrifugation and deslagging are conducted, thus obtaining a centrifugate; and freeze-drying: the clam extract freeze-dried powder is obtained through pre-freezing and first phase and second phase of sublimation. The extraction method is simple and effective, has effective components with the high content of bioactive proteins and is used for producing clam extract enteric-coated capsules to treat early, intermediate stage and terminal cancer patients such as lung cancer, liver cancer, renal carcinoma, carcinoma ventriculi, cervical carcinoma patients and the like.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

The invention discloses a medicinal composition for treating renal carcinoma. The medicinal composition is prepared from the following raw materials in parts by weight: 10-20 parts of desert cistanche, 10-30 parts of eucommia ulmoides, 10-20 parts of ginseng, 10-30 parts of rhizoma atractylodis macrocephalae, 10-20 parts of Chinese angelica, 10-30 parts of astragalus membranaceus, 10-30 parts of smoked plum, 10-30 parts of cynomorium songaricum, 10-20 parts of yam, 10-30 parts of pseudo-ginseng, 10-20 parts of pangolin scales, 10-30 parts of monkshood, 10-20 parts of tortoiseshell, 10-20 parts of turtle shell, 10-20 parts of dragon blood, 10-30 parts of sichuan lovage rhizome, 10-20 parts of salviae miltiorrhizae, 10-30 parts of nightshade, 10-30 parts of Indian strawberry, 10-20 parts of manyleaf paris rhizome, 10-20 parts of donkey-hide gelatin, 10-30 parts of indigo naturalis and 10-30 parts of mercurous chloride. The medicinal composition can be used for effectively treating renal carcinoma diseases and remarkably improving human disease resistance and promoting repairing of renal functions, and has the characteristics of good curative effect and little side effect.

A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.

The present invention relates to the chemically modified nucleic acid sequences of genomic DNA, to oligonucleotides and / or PNA-oligomers for detecting the cytosine methylation state of genomnic DNA, as well as to a method for ascertaining genetic and / or epigenetic parameters of genes for the characterizing, classifying and / or differentiating of renal and prostate carcinomas.

The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.

The invention belongs to the field of medical technology and discloses a renal carcinoma case digital information management system and method, and a terminal. The renal carcinoma case digital information management system comprises: a patient information acquisition module, a vimentin detection module, an image acquisition module, a central processing module, an image segmentation module, a pathologic analysis module, a data update module, and a display module. The system can detect the vimentin expression of a renal carcinoma patient without taking a renal carcinoma tissue by using the vimentin detection module. The technique is minimally invasive or even noninvasive, and can achieve detection in real time. Further, the image segmentation module performs operations by a computer so as togreatly reduce the manual sketching workload of a doctor and avoid errors caused by manual sketching. A segmentation result can be used for obtaining important anatomical and physiological parametersrequired for related disease diagnosis and surgical planning, thereby improving the efficiency and accuracy of disease diagnosis and treatment.

Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

A flaviviral replicon-based construct is provided for delivery and expression of granulocyte-macrophage colony stimulating factor to facilitate tumour therapy. In particular, the replicon construct encodes a Kunjin virus replicon having one or more mutations in an NS2A non-structural protein that induce enhanced levels of cellular IFN that synergize with recombinant granulocyte-macrophage colony stimulating factor delivered according to the invention. The construct may be administered intra-tumourally or peri-tumourally to an animal as DNA, RNA or packaged into a VLP, for the therapeutic and / or prophylactic treatment of tumours and cancers such as melanoma, lung carcinoma, cervical carcinoma, lung epithelial carcinoma, prostate cancer, breast cancer, renal carcinoma, colon cancer, epithelial cancers and mesothelioma.

The invention discloses novel Cembrane type diterpenoids with anti-tumor activities. In vitro anti-tumor activity study shows that the Cembrane type diterpenoids have strong anti-tumor activities on a plurality of kinds of tumor cells including gastric cancer, colon cancer, liver cancer or renal carcinoma and the like, and toxicity test study shows that the Cembrane type diterpenoids with anti-tumor activities have low toxicity and can be expected to be developed into novel antitumor drugs.

The present invention describes a method of using a molecular prognostic signature, to predict overall survival in patients with metastatic clear cell renal cell carcinoma. The present invention also describes a method of selecting therapy and a process for patient risk stratification based on the molecular prognostic signature analysis.

The invention discloses a miRNA biomarker and a detection kit which are used for renal cancer diagnosis. The microRNA biomarker is formed by the following microRNAs: hsa miR 10b 5p, hsa miR 384, hsa miR 206, hsa miR 424 5p and hsa miR 224 5p. According to the invention, serology expression analysis is carried out on five miRNAs obviously in differential expression of renal cancer and para-carcinoma tissues (differential expression quantity is more than 2 folds, and CT value in RT PCR is smaller than 30) hsa miR 10b 5p, hsa miR 384, hsa miR 424 5p, hsa miR 206 and hsa miR 224 5p, results show that the five miRNAs are stably expressed in serum, consistency between expression of serum miRNA and tissues is good, hsa miR 10b 5p, has miR 384 and has miR 206 are in down-regulated expression, and has miR 424 5p and has miR 224 5p are in up-regulated expression. The five miRNAs can serve as a biomarker used for the renal cancer diagnosis, and the sensitivity and specificity of combined diagnosis are obviously higher than those of single miRNA diagnosis.